Loading stock data…
INmune Bio Inc (INMB)
$2.51+0.07 (+2.87%)
Market ClosedLast close Sep 8
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
INmune Bio Inc. in the Healthcare sector is trading at $2.51 with a market capitalization of $33M. Wall Street consensus targets $7.00 (4 analysts), implying a +178.9% move over the next 12 months. The stock is currently near its 52-week high of $2.60, remaining 55.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +178.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.48M↑ | -$5.81M↓ | -$5.47M↑ | -$7.43M↑ | -$8.06M |
| Net Income | -$1.27M↑ | -$5.41M↓ | -$5.26M↑ | -$6.47M↑ | -$24.46M |
Peer Comparison
JNJUNHPFE
Fundamentals
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic ma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$33.36M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-211.99%
Volume
Today's trading volume
493,743
Recent News
INmune Bio (INMB) Q2 2026 Earnings Call Transcript
Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress.
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ...
INmune Bio Inc (INMB) secures MHRA alignment and advances commercial manufacturing, positioning for UK MAA submission while reducing net loss to $1.3 million.
INmune Bio, Inc. Q2 2026 Earnings Call Summary
Moby summary of INmune Bio, Inc.'s Q2 2026 earnings call
INmune Bio Q2 Earnings Call Highlights
INmune Bio (NASDAQ:INMB) outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second quarter of 2027. Ch
INmune Bio (INMB) Q4 2025 Earnings Transcript
David Moss: Thank you, Dan, and good afternoon, everyone. Thank you for joining us for INmune Bio's Fourth Quarter and Full Year 2025 Earnings Call. Mark will then provide an update on our CORDStrom platform with a focus on our RDEB program.